Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-278802
Filing Date
2025-11-13
Accepted
2025-11-13 07:00:54
Documents
52
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q evok-20250930.htm   iXBRL 10-Q 1847232
2 EX-31.1 evok-ex31_1.htm EX-31.1 15100
3 EX-31.2 evok-ex31_2.htm EX-31.2 15217
4 EX-32.1 evok-ex32_1.htm EX-32.1 10282
5 EX-32.2 evok-ex32_2.htm EX-32.2 10258
  Complete submission text file 0001193125-25-278802.txt   6980632

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT evok-20250930.xsd EX-101.SCH 962296
55 EXTRACTED XBRL INSTANCE DOCUMENT evok-20250930_htm.xml XML 1140491
Mailing Address 420 STEVENS AVENUE SUITE 230 SOLANA BEACH CA 92075
Business Address 420 STEVENS AVENUE SUITE 230 SOLANA BEACH CA 92075 858-345-1494
Evoke Pharma Inc (Filer) CIK: 0001403708 (see all company filings)

EIN.: 208447886 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36075 | Film No.: 251475335
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)